

# NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## Multiple Technology Appraisal

### Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma ID3760

#### Stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Eisai (lenvatinib)</li> <li>• Merck Sharp &amp; Dohme (pembrolizumab)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Black Health Agency for equality</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Cancer 52</li> <li>• Helen Rollason Cancer Charity</li> <li>• Independent Cancer Patients Voice</li> <li>• Kidney Cancer Support Network</li> <li>• Kidney Cancer UK</li> <li>• Kidney Care UK</li> <li>• Kidney Research UK</li> <li>• Macmillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie</li> <li>• National Kidney Federation</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Tenovus Cancer Care</li> <li>• UK Kidney Association</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> <li>• Association of Renal Technologists</li> <li>• British Association of Urological Nurses</li> <li>• British Association of Urological Surgeons</li> <li>• British Geriatrics Society</li> <li>• British Institute of Radiology</li> <li>• British Psychosocial Oncology Society</li> <li>• British Renal Society</li> <li>• British Society of Urogenital Radiology</li> <li>• British Uro-oncology Group</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Association of Renal Industries</li> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Association of Renal Industries</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Health Specialised Services Committee</li> <li>• Welsh Kidney Patients Association</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Bristol-Myers Squibb Pharmaceuticals (nivolumab, ipilimumab)</li> <li>• Eusa Pharma UK (tivozanib)</li> <li>• Ipsen (cabozantinib)</li> <li>• Novartis (pazopanib)</li> <li>• Pfizer (sunitinib)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Kidney and Transplant Group</li> <li>• Cochrane Urology</li> <li>• Cochrane UK</li> </ul>

Final stakeholder list for the multiple technology appraisal of lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma ID3760  
Issue date: October 2021

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Cancer Research UK</li> <li>• Renal Association</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Radiologists</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society and College of Radiographers</li> <li>• Society for DGH Nephrologists</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Oncology Nursing Society</li> <li>• UK Renal Pharmacy Group</li> <li>• Urology Foundation</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> <li>• NHS Brent CCG</li> <li>• NHS Hounslow CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Genomics England</li> <li>• Institute of Cancer Research</li> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> <li>• National Cancer Research Network</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

---

<sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.